Figures computed from official regulatory filings — .
Analysttarget 6 USD (+627%) · consensus 4.5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 5.02% · institutions 52.37% · short 0.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Rein Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
10 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| VON RICKENBACH JOSEF Htrack record | Buy | $4.8K | conv 34 |
| VON RICKENBACH JOSEF Htrack record | Buy | $24.5K | conv 49 | SEC |
| VON RICKENBACH JOSEF Htrack record | Buy | $3.6K | conv 51First in 12mo | SEC |
| VON RICKENBACH JOSEF Htrack record | Buy | $16.7K | conv 53 | SEC |
| WINDSOR JAMES BRIANtrack record | Buy | $25K | conv 72First in 12mo | SEC |
| WINDSOR JAMES BRIANtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Voss Value Master Fund, LPtrack record | Buy | $127.1K | conv 43First in 12mo | SEC |
| Voss Value-Oriented Special Situations Fund, LPtrack record | Buy | $126.9K | conv 21 | SEC |
| Voss Value-Oriented Special Situations Fund, LPtrack record | Buy | $6.6K | conv 18 | SEC |
| Voss Value-Oriented Special Situations Fund, LPtrack record | Buy | $248K | conv 43 | SEC |
| Voss Value-Oriented Special Situations Fund, LPtrack record | Buy | $41.9K | conv 30First in 12mo | SEC |
| Ambros Reinhard J. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fairey William | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aivado Manuel | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| VON RICKENBACH JOSEF Htrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Musso Alan A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |